For instance, Nehar et al. reported that in patients with GEP-NETs and multiple endocrine neoplasia (MEN) who were treated mainly with somatostatin analogs (SSAs), CgA levels and tumor size were closely associated with each other in up to 80% of cases [10]. This evidence concerns the gene CGA and multiple endocrine neoplasia.